Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00762710 · ClinicalTrials.gov registry record · Phase 2

Study of the Medication Prazosin for Alcohol Dependence

A Phase 2 study, sponsored by Seattle Institute for Biomedical and Clinical Research.

Completed
Registry status
Phase 2
Development phase
92
Enrollment target

NCT00762710 is a Phase 2 study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 92 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00762710, a Phase 2 study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.

COMPLETED
Registry status
Phase 2
Development phase
92 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency.

Interventions

  • DRUG Placebo medication
  • DRUG Prazosin medication

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2008-01
Est. Completion 2014-06
Phase Phase 2

What the Registry Record Tells You About NCT00762710

The ClinicalTrials.gov registry entry for NCT00762710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo medication is the first listed.

NCT00762710 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00762710 about?

NCT00762710 is a clinical study titled "Study of the Medication Prazosin for Alcohol Dependence". The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency.

What is the current status of trial NCT00762710?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2008-01. Estimated completion is 2014-06.

What interventions are being tested in trial NCT00762710?

The interventions under investigation include: Placebo medication (DRUG), Prazosin medication (DRUG).

Who is sponsoring clinical trial NCT00762710?

This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.